Free Trial
→ A weekly dividend fund holding Nvidia and Palantir (From Investors Alley) (Ad)tc pixel Free CELU Stock Alerts

Celularity (CELU) Financials

Celularity logo
$1.25 -0.08 (-6.02%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$1.25 +0.00 (+0.40%)
As of 10/16/2026 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Celularity

Annual Income Statements for Celularity

This table shows Celularity's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 5.88 -208 -100 14 -193 -58 -92
Consolidated Net Income / (Loss)		 5.88 -208 -100 14 -196 -58 -92
Net Income / (Loss) Continuing Operations		 5.88 -208 -100 14 -193 -58 -92
Total Pre-Tax Income 		6.55 -213 -100 14 -196 -58 -92
Total Revenue		 3.75 -4.43 0.00 0.00 0.00 0.00 0.00
Net Interest Income / (Expense)		 3.75 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Income		 3.75 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Non-Interest Income		 -0.01 -4.43 0.00 0.00 0.00 0.00 0.00
Total Non-Interest Expense		 1.68 211 109 26 189 48 70
Marketing Expense		 - 53 88 78 30 17 15
Other Operating Expenses		 - 95 81 86 66 83 81
Amortization Expense		 - 3.39 2.19 2.19 2.19 1.75 1.49
Restructuring Charge		 - -56 -41 -126 - -0.19 0.00
Other Special Charges		 1.68 -14 -21 -18 -23 -54 -27
Nonoperating Income / (Expense), net		 4.49 2.11 8.96 40 -4.00 -9.94 -21
Income Tax Expense		 0.67 -4.70 0.02 0.01 0.01 0.00 0.00
Preferred Stock Dividends Declared		 - - - - - 0.00 0.08
Basic Earnings per Share		 $0.47 ($11.31) ($1.49) $1.01 ($11.02) ($2.64) ($3.59)
Weighted Average Basic Shares Outstanding		 9.09M 18.42M 67.06M 13.99M 17.81M 21.89M 25.60M
Diluted Earnings per Share		 $0.47 ($11.31) ($1.49) $0.95 ($11.02) ($2.64) ($3.59)
Weighted Average Diluted Shares Outstanding		 9.09M 18.42M 67.06M 14.98M 17.81M 21.89M 25.60M

Quarterly Income Statements for Celularity

This table shows Celularity's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -94 11 -22 -6.49 -16 -13 -20 -25 -23 -24 0.68
Consolidated Net Income / (Loss)		 -94 9.55 -22 -6.49 -16 -13 -20 -25 -23 -24 0.87
Net Income / (Loss) Continuing Operations		 -94 11 -20 -6.03 -16 -16 -22 -24 -20 -28 1.17
Total Pre-Tax Income 		-94 9.56 -22 -6.49 -16 -13 -20 -25 -23 -14 -9.83
Total Revenue		 0.00 -3.94 15 0.00 0.00 -15 0.00 0.00 0.00 -17 3.85
Net Interest Income / (Expense)		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Interest Income		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Interest Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Non-Interest Income		 0.00 -3.94 15 0.00 0.00 -15 0.00 0.00 0.00 -17 3.85
Other Non-Interest Income		 - - 15 - - - - - - - 3.85
Total Non-Interest Expense		 99 -21 20 9.72 11 6.67 20 15 13 15 13
Marketing Expense		 5.18 -0.27 5.84 3.80 3.92 3.83 - 3.35 4.60 3.35 2.99
Other Operating Expenses		 15 0.10 14 18 17 35 14 18 13 26 9.17
Amortization Expense		 0.55 0.55 0.55 - - - 0.37 - - - 0.37
Nonoperating Income / (Expense), net		 5.38 -3.76 -15 3.69 -4.57 5.59 - -8.66 -7.27 3.98 -1.15
Other Gains / (Losses), net		 - - - - - - -1.40 - - - 11
Preferred Stock Dividends Declared		 - - 0.00 0.00 0.00 - - 0.00 0.00 - 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - - - - - 0.20
Basic Earnings per Share		 ($4.98) $0.63 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95) $0.02
Weighted Average Basic Shares Outstanding		 18.83M 17.81M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M 29.07M
Diluted Earnings per Share		 ($4.98) $0.63 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95) $0.02
Weighted Average Diluted Shares Outstanding		 18.83M 17.81M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M 30.30M

Annual Cash Flow Statements for Celularity

This table details how cash moves in and out of Celularity's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.89 26 -17 -23 -19 0.81 5.40
Net Cash From Operating Activities		 -1.10 -63 -110 -138 -39 -6.40 -13
Net Cash From Continuing Operating Activities		 -1.10 -63 -110 -138 -39 -6.40 -13
Net Income / (Loss) Continuing Operations		 5.88 -208 -100 14 -196 -58 -92
Consolidated Net Income / (Loss)		 5.88 -208 -100 14 -196 -58 -92
Provision For Loan Losses		 - 0.29 0.30 1.88 1.23 0.46 1.35
Depreciation Expense		 - 8.17 8.82 9.44 9.32 7.92 7.30
Amortization Expense		 - 0.06 - - - 0.00 -1.91
Non-Cash Adjustments to Reconcile Net Income		 -7.11 137 -9.28 -145 140 21 38
Changes in Operating Assets and Liabilities, net		 0.14 -0.09 -9.81 -18 7.41 23 34
Net Cash From Investing Activities		 -287 -13 -5.90 -5.24 -4.05 0.51 0.00
Net Cash From Continuing Investing Activities		 -287 -13 -5.90 -5.24 -4.05 0.51 0.00
Purchase of Property, Leasehold Improvements and Equipment		 - -28 -6.20 -5.24 -1.05 -0.16 0.00
Purchase of Investment Securities		 -288 - - 0.00 -3.00 -1.50 0.00
Sale and/or Maturity of Investments		 - 0.00 0.30 - 0.00 2.18 0.00
Net Cash From Financing Activities		 289 102 99 120 24 6.70 19
Net Cash From Continuing Financing Activities		 289 102 99 120 24 6.70 19
Issuance of Debt		 0.13 0.00 5.00 86 20 19 20
Issuance of Preferred Equity		 - 103 - - - 6.00 2.00
Issuance of Common Equity		 7.00 0.00 83 37 22 0.00 1.04
Repayment of Debt		 -0.28 -0.40 -16 -2.60 -18 -18 -8.65
Other Financing Activities, Net		 282 0.14 26 0.23 0.20 -0.40 4.17
Cash Interest Paid		 - 0.00 0.15 0.00 1.07 0.14 2.50
Cash Income Taxes Paid		 0.65 0.01 0.00 0.00 - 0.00 0.05

Quarterly Cash Flow Statements for Celularity

This table details how cash moves in and out of Celularity's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.81 -4.94 1.79 -1.39 -0.22 0.65 -0.67 0.63 -0.68 6.12 -5.90
Net Cash From Operating Activities		 -8.32 -4.34 -4.40 -3.45 -0.14 1.59 -2.99 -1.00 -4.16 -5.10 1.45
Net Cash From Continuing Operating Activities		 -8.32 -4.34 -4.40 -3.45 -0.14 1.59 -2.99 -1.00 -4.16 -5.10 1.45
Net Income / (Loss) Continuing Operations		 -94 9.55 -22 -6.49 -16 -13 -20 -25 -23 -24 0.87
Consolidated Net Income / (Loss)		 -94 9.55 -22 -6.49 -16 -13 -20 -25 -23 -24 0.87
Provision For Loan Losses		 0.08 0.78 0.20 0.11 -0.08 0.24 -0.06 0.01 -0.10 1.50 0.20
Depreciation Expense		 2.34 2.30 2.16 2.00 1.89 1.88 1.83 1.83 1.82 1.80 1.60
Non-Cash Adjustments to Reconcile Net Income		 80 12 17 -6.12 7.11 2.44 11 6.92 11 9.91 2.37
Changes in Operating Assets and Liabilities, net		 2.95 -29 -1.93 7.06 7.03 10 4.29 15 6.65 7.91 -3.59
Net Cash From Investing Activities		 -0.23 -0.58 -0.04 2.14 - -1.59 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 -0.23 -0.58 -0.04 2.14 - -1.59 0.00 - - - 0.00
Net Cash From Financing Activities		 5.74 -0.01 6.23 -0.09 -0.08 0.64 2.32 1.63 3.48 11 -7.34
Net Cash From Continuing Financing Activities		 5.74 -0.01 6.23 -0.09 -0.08 0.64 2.32 1.63 3.48 11 -7.34
Issuance of Common Equity		 3.00 - 6.00 - - -6.00 2.46 1.01 -0.44 -2.00 0.00
Repayment of Debt		 -0.26 - -17 -0.12 0.02 -0.04 -0.04 -0.26 -6.78 -1.57 -7.34
Other Financing Activities, Net		 -0.00 -0.01 -0.38 0.03 -0.10 0.05 -0.10 0.88 1.60 1.79 0.00

Annual Balance Sheets for Celularity

This table presents Celularity's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.17 292 431 414 401 144 133 107
Cash and Due from Banks		 0.02 0.92 54 37 14 0.23 0.74 6.18
Restricted Cash		 - - 15 15 15 9.94 10 10
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 - - 90 91 76 68 62 56
Goodwill		 - - 123 123 120 7.35 7.35 7.35
Intangible Assets		 - - 125 123 121 11 9.25 7.76
Other Assets		 0.00 291 23 25 56 48 44 20
Total Liabilities & Shareholders' Equity		 0.17 292 431 414 401 144 133 107
Total Liabilities		 0.15 28 412 315 202 103 124 145
Short-Term Debt		 0.00 0.02 5.39 9.32 43 53 30 43
Accrued Interest Payable		 - - 13 12 16 11 20 33
Other Short-Term Payables		 0.15 0.21 7.84 5.25 2.27 2.83 3.53 5.65
Other Long-Term Liabilities		 0.00 28 358 260 140 36 34 65
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 5.00 -531 99 199 41 8.84 -38
Total Preferred & Common Equity		 0.02 5.00 -531 99 199 41 8.84 -38
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.02 5.00 -531 99 199 41 8.84 -38
Common Stock		 0.03 1.12 32 763 844 883 909 953
Retained Earnings		 -0.00 3.88 -564 -664 -645 -842 -900 -991
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.01 0.00 -0.01 0.00

Quarterly Balance Sheets for Celularity

This table presents Celularity's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 157 144 135 129 129 120 114 99
Cash and Due from Banks		 0.27 1.90 0.47 0.13 0.29 0.86 0.12 0.37
Restricted Cash		 15 10 10 10 10 10 10 10
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 71 66 65 63 60 59 57 55
Goodwill		 7.35 7.35 7.35 7.35 7.35 7.35 7.35 7.35
Intangible Assets		 12 10 10.00 9.62 8.88 8.51 8.13 7.39
Other Assets		 53 48 43 38 42 35 28 20
Total Liabilities & Shareholders' Equity		 157 144 135 129 129 120 114 99
Total Liabilities		 127 113 108 112 134 146 134 135
Short-Term Debt		 48 53 55 58 30 31 30 36
Accrued Interest Payable		 34 10 10 14 25 33 29 31
Other Short-Term Payables		 2.46 2.81 2.79 3.69 3.48 3.50 5.58 4.12
Other Long-Term Liabilities		 42 47 40 35 39 40 69 64
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 30 31 28 17 -5.51 -25 -20 -35
Total Preferred & Common Equity		 30 31 28 17 -5.51 -25 -20 -35
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 30 31 28 17 -5.51 -25 -20 -35
Common Stock		 879 895 898 904 914 919 947 955
Retained Earnings		 -851 -864 -870 -886 -920 -944 -967 -991
Accumulated Other Comprehensive Income / (Loss)		 2.40 - - -0.00 0.00 -0.00 0.00 0.00

Annual Metrics And Ratios for Celularity

This table displays calculated financial ratios and metrics derived from Celularity's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 35,937,500.00 35,937,500.00 123,464,113.00 145,013,313.00 193,781,641.00 22,484,239.00 28,328,880.00
DEI Adjusted Shares Outstanding		 3,593,750.00 3,593,750.00 12,346,411.00 14,501,331.00 19,378,164.00 22,484,239.00 28,328,880.00
DEI Earnings Per Adjusted Shares Outstanding		 1.64 -57.94 -8.11 0.98 -10.13 -2.57 -3.24
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -218.38% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -10,129.78% 51.53% 83.88% -1,010.22% 77.68% -62.59%
EBIT Growth		 0.00% -10,528.95% 49.29% 76.53% -637.29% 74.58% -46.96%
NOPAT Growth		 0.00% -8,230.08% 49.29% 66.50% -426.27% 75.06% -46.98%
Net Income Growth		 0.00% -3,642.12% 51.92% 114.18% -1,483.14% 70.51% -58.43%
EPS Growth		 0.00% -2,506.38% 86.83% 114.18% -1,483.14% 76.04% -35.98%
Operating Cash Flow Growth		 0.00% -5,656.16% -74.22% -25.23% 71.94% 83.45% -107.06%
Free Cash Flow Firm Growth		 0.00% 0.00% -364.01% 18.80% 110.20% -202.08% 250.97%
Invested Capital Growth		 0.00% -80.36% 164.45% 77.10% -61.07% -21.12% -93.99%
Revenue Q/Q Growth		 0.00% 0.00% 100.00% 0.00% -100.00% -100.00% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% 60.85% 66.20% 0.11% -3,628.12% -51.16%
EBIT Q/Q Growth		 0.00% 0.00% 58.70% 55.42% 0.18% -409.37% -39.75%
NOPAT Q/Q Growth		 0.00% 0.00% 58.70% 37.04% -2.22% -204.24% -7.08%
Net Income Q/Q Growth		 0.00% 0.00% 60.31% 199.37% -8.21% -65.16% -13.73%
EPS Q/Q Growth		 0.00% 0.00% 37.13% 199.37% -8.21% -73.68% -22.95%
Operating Cash Flow Q/Q Growth		 0.00% -35.65% -16.03% 1.75% 39.49% 48.11% -102.14%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -7.38% 370.40% -67.61% 8.46%
Invested Capital Q/Q Growth		 0.00% 0.00% 4.23% 13.92% 20.67% -1.15% -56.18%
Profitability Metrics		 - - - - - - -
EBITDA Margin		 55.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 55.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 156.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 89.79% 97.79% 100.02% 99.91% 100.01% 100.00% 100.00%
Interest Burden Percent		 317.51% 99.02% 91.78% -55.51% 104.03% 120.70% 130.12%
Effective Tax Rate		 10.21% 0.00% 0.00% 0.09% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 21,327.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 1.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2.23% -147.63% -169.50% 9.51% -163.67% -232.51% 627.65%
Cash Return on Invested Capital (CROIC)		 0.00% 38.80% -171.22% -69.14% 7.94% -16.17% 52.23%
Operating Return on Assets (OROA)		 1.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 4.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.04% 275.47% 619.84% 9.51% -163.67% -232.51% 627.65%
Return on Equity Simple (ROE_SIMPLE)		 117.59% 39.19% -100.70% 7.14% -479.24% -655.11% 240.96%
Net Operating Profit after Tax (NOPAT)		 1.85 -151 -76 -26 -135 -34 -49
NOPAT Margin		 49.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -21,327.29% 349.25% 67.52% -98.42% 127.47% 40.89% 78.38%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 44.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 2.06 -215 -109 -26 -189 -48 -70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.06 -207 -100 -16 -179 -40 -65
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 71.53 0.00 6.36 0.94 1.15 5.29 0.00
Price to Tangible Book Value (P/TBV)		 71.53 0.00 0.00 0.00 2.09 0.00 0.00
Price to Revenue (P/Rev)		 95.47 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 60.83 0.00 0.00 13.18 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.64% 0.00% 0.00% 7.59% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.34 17.57 4.51 0.83 0.96 1.36 12.87
Enterprise Value to Revenue (EV/Rev)		 164.22 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 298.29 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 298.29 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 332.20 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 14.87 0.00 0.00 6.77 0.00 2.80
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 1.76 0.38 0.22 1.30 7.42 -1.12
Long-Term Debt to Equity		 0.00 1.48 0.28 0.00 0.00 4.07 0.00
Financial Leverage		 0.00 0.12 0.60 0.27 0.40 2.39 -3.70
Leverage Ratio		 1.11 2.56 7.15 2.73 2.27 5.55 -8.21
Compound Leverage Factor		 3.52 2.54 6.57 -1.52 2.36 6.70 -10.69
Debt to Total Capital		 0.01% 63.83% 27.34% 17.92% 56.58% 88.13% 950.36%
Short-Term Debt to Total Capital		 0.01% 10.42% 6.81% 17.92% 56.58% 39.85% 950.36%
Long-Term Debt to Total Capital		 0.00% 53.41% 20.53% 0.00% 0.00% 48.28% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 98.09% 1,063.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 1.90% -1,027.12% 72.66% 82.08% 43.42% 11.87% -850.36%
Debt to EBITDA		 0.01 -0.16 -0.37 -2.69 -0.30 -1.64 -0.65
Net Debt to EBITDA		 -0.44 0.18 0.15 -0.90 -0.24 -1.36 -0.40
Long-Term Debt to EBITDA		 0.00 -0.13 -0.28 0.00 0.00 -0.90 0.00
Debt to NOPAT		 0.01 -0.22 -0.49 -1.70 -0.40 -1.95 -0.86
Net Debt to NOPAT		 -0.49 0.24 0.19 -0.57 -0.32 -1.63 -0.53
Long-Term Debt to NOPAT		 0.00 -0.18 -0.37 0.00 0.00 -1.07 0.00
Noncontrolling Interest Sharing Ratio		 98.09% 286.60% 465.68% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 61 -161 -131 13 -14 21
Operating Cash Flow to CapEx		 0.00% -227.04% -1,774.88% -2,633.23% -3,691.32% -3,975.78% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 263 52 137 242 94 74 4.48
Invested Capital Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -212 85 105 -148 -20 -70
Enterprise Value (EV)		 615 909 617 202 90 101 58
Market Capitalization		 358 395 632 187 47 47 31
Book Value per Share		 $0.14 ($14.79) $0.81 $1.37 $0.21 $0.39 ($1.34)
Tangible Book Value per Share		 $0.14 ($21.71) ($1.19) ($0.29) $0.12 ($0.35) ($1.88)
Total Capital		 263 52 137 242 94 74 4.48
Total Debt		 0.02 33 37 43 53 66 43
Total Long-Term Debt		 0.00 28 28 0.00 0.00 36 0.00
Net Debt		 -0.90 -36 -15 15 43 55 26
Capital Expenditures (CapEx)		 0.00 28 6.20 5.24 1.05 0.16 0.00
Net Nonoperating Expense (NNE)		 -4.03 58 24 -40 62 24 42
Net Nonoperating Obligations (NNO)		 0.02 33 37 43 53 66 43
Total Depreciation and Amortization (D&A)		 0.00 8.23 8.82 9.44 9.32 7.92 5.38
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($0.30) $0.00 ($14.90) $1.00 ($11.02) ($2.64) ($3.59)
Adjusted Weighted Average Basic Shares Outstanding		 3.59M 0.00 13.77M 13.99M 17.81M 21.89M 25.60M
Adjusted Diluted Earnings per Share		 ($0.30) $0.00 ($14.90) $0.90 ($11.02) ($2.64) ($3.59)
Adjusted Weighted Average Diluted Shares Outstanding		 3.59M 0.00 13.77M 14.98M 17.81M 21.89M 25.60M
Adjusted Basic & Diluted Earnings per Share		 ($0.30) $0.00 ($14.90) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 801.54K 0.00 6.71M 16.50M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 3.36 -109 -120 -166 -72 -72 -68
Normalized NOPAT Margin		 89.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 174.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.12% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Celularity

This table displays calculated financial ratios and metrics derived from Celularity's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 190,948,190.00 193,781,641.00 193,781,641.00 193,781,641.00 21,984,614.00 22,484,239.00 22,484,239.00 23,949,229.00 26,691,477.00 28,328,880.00 28,328,880.00
DEI Adjusted Shares Outstanding		 19,094,819.00 19,378,164.00 19,378,164.00 19,378,164.00 21,984,614.00 22,484,239.00 22,484,239.00 23,949,229.00 26,691,477.00 28,328,880.00 28,328,880.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.92 0.49 -1.14 -0.33 -0.73 -0.59 -0.88 -1.02 -0.86 -0.86 0.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 273.09% 0.00% 0.00% -273.09% 17.10% 0.00% 0.00% -17.10% 0.00%
EBITDA Growth		 -3,113.30% 0.98% 94.18% 80.89% 90.45% -199.96% -141.20% -76.85% -15.58% -64.57% 61.77%
EBIT Growth		 -1,734.68% 1.97% 91.02% 77.26% 88.76% -224.22% -82.51% -59.40% -12.30% -49.84% 57.38%
NOPAT Growth		 -1,126.23% -23.89% 88.45% 76.05% 88.39% -199.36% -184.33% -55.91% -37.10% 5.46% 57.38%
Net Income Growth		 -2,056.16% -60.93% 65.61% 86.47% 82.85% -239.24% 10.26% -277.99% -43.35% -83.27% 104.42%
EPS Growth		 -2,056.16% -60.93% 75.00% 88.97% 85.34% -196.83% 18.45% -240.00% -20.55% -55.74% 102.38%
Operating Cash Flow Growth		 77.94% 85.33% 70.64% 68.73% 98.27% 136.72% 32.02% 71.03% -2,788.19% -420.14% 148.35%
Free Cash Flow Firm Growth		 174.68% 283.22% 176.76% 320.02% -107.96% -95.84% -92.43% -61.28% 1,143.33% 756.49% 518.76%
Invested Capital Growth		 -63.24% -61.07% -58.00% -49.92% -3.70% -21.12% -27.46% -48.70% -86.43% -93.99% -99.50%
Revenue Q/Q Growth		 0.00% 0.00% 473.09% -100.00% 0.00% 0.00% 217.10% -100.00% 0.00% 0.00% 122.37%
EBITDA Q/Q Growth		 -139.75% 120.11% -118.37% -115.73% -19.88% -110.40% -13.62% -58.17% 21.66% -199.59% 77.90%
EBIT Q/Q Growth		 -132.20% 117.32% -133.37% -69.44% -14.74% -91.49% -10.48% -47.98% 19.16% -155.50% 72.87%
NOPAT Q/Q Growth		 -133.68% 119.14% -138.82% -37.95% -13.29% -63.78% -59.02% 24.36% 0.38% -12.94% 51.36%
Net Income Q/Q Growth		 -95.78% 110.17% -330.58% 70.53% -148.12% 17.42% -48.60% -24.15% 5.90% -5.57% 103.59%
EPS Q/Q Growth		 -95.78% 110.17% -263.49% 70.87% -143.33% 16.44% -64.71% -21.43% 13.73% -7.95% 102.11%
Operating Cash Flow Q/Q Growth		 24.53% 47.84% -1.43% 21.69% 95.82% 1,206.94% -287.77% 66.62% -316.32% -22.70% 128.36%
Free Cash Flow Firm Q/Q Growth		 290.47% 147.94% -31.25% -32.24% -106.89% 229.57% -21.47% 246.51% 85.67% 6.37% -5.01%
Invested Capital Q/Q Growth		 -52.56% 20.67% -10.93% -1.78% -8.78% -1.15% -18.10% -30.54% -75.87% -56.18% -93.25%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 0.00% 0.00% -24.39% 0.00% 0.00% 0.00% -50.23% 0.00% 0.00% 0.00% -184.19%
EBIT Margin		 0.00% 0.00% -39.07% 0.00% 0.00% 0.00% -60.89% 0.00% 0.00% 0.00% -225.72%
Profit (Net Income) Margin		 0.00% 0.00% -149.94% 0.00% 0.00% 0.00% -114.90% 0.00% 0.00% 0.00% 22.72%
Tax Burden Percent		 100.00% 99.90% 100.00% 100.00% 100.00% 100.00% 65.32% 100.00% 100.00% 175.61% -8.89%
Interest Burden Percent		 94.58% 55.59% 383.77% 66.76% 144.35% 62.25% 288.85% 158.30% 184.25% 43.35% 113.27%
Effective Tax Rate		 0.00% 0.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -2.66% 0.00% 0.00% 0.00% -2.96% 0.00% 0.00% 0.00% -19.84%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -37.32% 0.00% 0.00% 0.00% -11.47% 0.00% 0.00% 0.00% -6.22%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -19.42% 0.00% 0.00% 0.00% -53.13% 0.00% 0.00% 0.00% 15.55%
Return on Equity (ROE)		 0.00% -163.67% -22.08% 0.00% 0.00% -232.51% -56.08% 0.00% 0.00% 627.65% -4.29%
Cash Return on Invested Capital (CROIC)		 1.95% 7.94% 14.78% 7.93% -10.61% -16.17% -22.11% -4.63% 44.43% 52.23% 12.49%
Operating Return on Assets (OROA)		 0.00% 0.00% -1.66% 0.00% 0.00% 0.00% -1.12% 0.00% 0.00% 0.00% -7.60%
Return on Assets (ROA)		 0.00% 0.00% -6.37% 0.00% 0.00% 0.00% -2.12% 0.00% 0.00% 0.00% 0.77%
Return on Common Equity (ROCE)		 0.00% -163.67% -22.08% 0.00% 0.00% -232.51% -56.08% 0.00% 0.00% 627.65% -4.29%
Return on Equity Simple (ROE_SIMPLE)		 -599.76% 0.00% -493.81% -405.70% -202.85% 0.00% 1,010.41% 288.93% 401.35% 0.00% 201.61%
Net Operating Profit after Tax (NOPAT)		 -69 13 -5.16 -7.12 -8.07 -13 -15 -11 -11 -12 -6.08
NOPAT Margin		 0.00% 0.00% -35.17% 0.00% 0.00% 0.00% -85.39% 0.00% 0.00% 0.00% -158.00%
Net Nonoperating Expense Percent (NNEP)		 50.61% 7.76% 34.66% -1.26% 15.16% 0.13% 8.51% 21.90% 27.20% 21.95% -13.63%
SG&A Expenses to Revenue		 0.00% 0.00% 39.80% 0.00% 0.00% 0.00% 21.68% 0.00% 0.00% 0.00% 77.85%
Operating Expenses to Revenue		 0.00% 0.00% 139.07% 0.00% 0.00% 0.00% 160.89% 0.00% 0.00% 0.00% 325.72%
Earnings before Interest and Taxes (EBIT)		 -99 17 -5.74 -9.72 -11 -21 -10 -15 -13 -32 -8.68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -97 19 -3.58 -7.72 -9.26 -19 -8.64 -14 -11 -32 -7.08
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.40 1.15 3.24 2.18 3.78 5.29 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.74 2.09 7.54 5.80 211.31 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 10.78 0.00 9.43 5.64 6.08 0.00 15.49 18.69 22.00 0.00 9.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.96 0.96 1.69 1.27 1.50 1.36 1.56 2.45 7.37 12.87 207.83
Enterprise Value to Revenue (EV/Rev)		 19.12 0.00 13.23 9.75 10.52 0.00 37.85 41.35 29.99 0.00 16.32
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 26.48 6.77 6.77 10.68 0.00 0.00 0.00 0.00 3.96 2.80 16.41
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.58 1.30 1.69 1.97 3.36 7.42 -12.07 -2.66 -1.51 -1.12 -1.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 4.07 -6.63 -1.43 0.00 0.00 0.00
Financial Leverage		 0.50 0.40 0.52 0.69 2.23 2.39 4.63 52.97 -31.39 -3.70 -2.50
Leverage Ratio		 3.06 2.27 2.71 2.61 6.02 5.55 10.59 110.53 -86.38 -8.21 -5.60
Compound Leverage Factor		 2.89 1.26 10.40 1.74 8.69 3.46 30.60 174.98 -159.16 -3.56 -6.34
Debt to Total Capital		 61.31% 56.58% 62.82% 66.30% 77.05% 88.13% 109.03% 160.22% 296.71% 950.36% 11,775.83%
Short-Term Debt to Total Capital		 61.31% 56.58% 62.82% 66.30% 77.05% 39.85% 49.16% 74.03% 296.71% 950.36% 11,775.83%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 48.28% 59.87% 86.19% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 38.69% 43.42% 37.18% 33.70% 22.95% 11.87% -9.03% -60.22% -196.71% -850.36% -11,675.83%
Debt to EBITDA		 -0.27 -0.30 -0.43 -0.62 -54.01 -1.64 -1.86 -1.63 -0.70 -0.65 -0.69
Net Debt to EBITDA		 -0.18 -0.24 -0.34 -0.50 -44.43 -1.36 -1.57 -1.37 -0.47 -0.40 -0.48
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.90 -1.02 -0.88 0.00 0.00 0.00
Debt to NOPAT		 -0.36 -0.40 -0.56 -0.76 -5.26 -1.95 -1.70 -1.57 -0.66 -0.86 -0.63
Net Debt to NOPAT		 -0.25 -0.32 -0.43 -0.61 -4.32 -1.63 -1.44 -1.32 -0.44 -0.53 -0.44
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -1.07 -0.93 -0.85 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 65 161 111 75 -5.18 6.71 8.40 29 54 57 55
Operating Cash Flow to CapEx		 -3,650.00% -748.45% -11,289.74% -11,122.58% 0.00% 1,751.65% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.04 0.06 0.08 0.00 0.02 0.02 0.02 0.00 0.03
Fixed Asset Turnover		 0.05 0.00 0.15 0.16 0.16 0.00 0.04 0.04 0.04 0.00 0.07
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 78 94 84 83 75 74 61 42 10 4.48 0.30
Invested Capital Turnover		 0.03 0.00 0.08 0.09 0.14 0.00 0.03 0.04 0.06 0.00 0.13
Increase / (Decrease) in Invested Capital		 -135 -148 -116 -82 -2.89 -20 -23 -40 -65 -70 -61
Enterprise Value (EV)		 75 90 142 105 113 101 95 104 75 58 63
Market Capitalization		 42 47 101 61 65 47 39 47 55 31 38
Book Value per Share		 $0.16 $0.21 $0.16 $0.14 $0.79 $0.39 ($0.24) ($1.06) ($0.75) ($1.34) ($1.24)
Tangible Book Value per Share		 $0.06 $0.12 $0.07 $0.05 $0.01 ($0.35) ($0.97) ($1.72) ($1.33) ($1.88) ($1.76)
Total Capital		 78 94 84 83 75 74 61 42 10 4.48 0.30
Total Debt		 48 53 53 55 58 66 66 68 30 43 36
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 36 36 36 0.00 0.00 0.00
Net Debt		 33 43 41 44 48 55 56 57 20 26 25
Capital Expenditures (CapEx)		 0.23 0.58 0.04 0.03 0.00 0.09 0.00 0.00 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 24 3.75 17 -0.63 8.03 0.08 5.07 13 12 12 -6.95
Net Nonoperating Obligations (NNO)		 48 53 53 55 58 66 66 68 30 43 36
Total Depreciation and Amortization (D&A)		 2.34 2.30 2.16 2.00 1.89 1.88 1.83 1.83 1.82 -0.06 1.60
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.00) $6.30 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95) $0.02
Adjusted Weighted Average Basic Shares Outstanding		 18.83M 1.78M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M 29.07M
Adjusted Diluted Earnings per Share		 ($5.00) $6.30 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95) $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 18.83M 1.78M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M 30.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $6.30 $0.00 $0.00 $0.00 ($0.61) $0.00 $0.00 $0.00 ($0.95) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 22.48M 0.00 0.00 26.69M 28.33M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -94 -5.16 -16 -15 -13 -15 -15 -15 -23 -6.08
Normalized NOPAT Margin		 0.00% 0.00% -35.17% 0.00% 0.00% 0.00% -86.38% 0.00% 0.00% 0.00% -158.00%
Pre Tax Income Margin		 0.00% 0.00% -149.94% 0.00% 0.00% 0.00% -175.90% 0.00% 0.00% 0.00% -255.67%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Celularity’s latest quarter shows a sharp improvement in reported profitability and operating cash flow, but the underlying financial position remains highly leveraged and dependent on nonrecurring items and external financing. The company reported $3.8 million of revenue in Q1 2026, compared with no revenue in each of the available Q1–Q3 2025 statements. Consolidated net income was $874,000, and net income attributable to common shareholders was $675,000, or $0.02 per diluted share.

  • Q1 2026 marked a significant earnings improvement. Celularity moved from a $24.4 million consolidated loss in Q4 2025 and a $23.1 million loss in Q3 2025 to $874,000 of consolidated net income. Diluted EPS improved to $0.02 from a loss of $0.95 in Q4 2025.
  • Operating cash flow turned positive. Net cash from operating activities was $1.4 million in Q1 2026, following cash outflows of $5.1 million in Q4 2025, $4.2 million in Q3, $1.0 million in Q2 and $3.0 million in Q1 2025.
  • Reported revenue returned in Q1 2026. Revenue of $3.8 million compares favorably with zero reported revenue in the preceding three 2025 quarters and may indicate progress in commercial activity.
  • Debt repayment reduced financing cash outflows. Celularity repaid $7.3 million of debt in Q1 2026, compared with $1.6 million in Q4 2025 and $6.8 million in Q3 2025. This suggests some progress in reducing obligations, although leverage remains elevated.
  • The earnings improvement was not primarily generated by core operations. Pretax income remained negative at $9.8 million, while the company recorded an $11.0 million gain below pretax income. Without that gain, Q1 2026 would have remained unprofitable.
  • Cash resources are concentrated in restricted cash. Q1 2026 cash and due from banks totaled only $368,000, while restricted cash was $10.1 million. The combined balance was approximately $10.4 million, but restricted funds may not be readily available for general corporate needs.
  • Celularity continues to have negative shareholders’ equity. Total equity deteriorated from positive equity of $31.2 million in Q1 2024 and $17.3 million in Q3 2024 to negative $35.3 million in Q1 2026. Total liabilities of $134.7 million exceeded total assets of $99.5 million.
  • Interest-related and other obligations remain substantial. Q1 2026 included $35.6 million of short-term debt, $30.9 million of accrued interest payable and $64.2 million of other long-term liabilities. These obligations create significant refinancing and liquidity risk.
  • The company has a long history of operating losses and cash burn. Q1–Q4 2025 all showed sizeable net losses, and operating cash flow was negative in each reported 2025 quarter except Q1 2026. The latest positive operating cash flow therefore has not yet established a sustained trend.
  • Share dilution has increased over time. Basic weighted-average shares outstanding rose from 21.4 million in Q1 2024 to 29.1 million in Q1 2026, while diluted shares reached 30.3 million. Future equity financing could provide liquidity but may further reduce existing shareholders’ ownership.

Overall, Q1 2026 provides encouraging signs through the return of revenue, positive net income and positive operating cash flow. However, the gain-driven nature of profitability, restricted liquidity, negative equity and significant liabilities mean investors should look for continued revenue growth, recurring operating profitability and additional debt reduction before concluding that Celularity’s financial recovery is durable.

10/18/26 09:09 AM ETAI Generated. May Contain Errors.

Celularity Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Celularity's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Celularity's net income appears to be on a downward trend, with a most recent value of -$91.72 million in 2025, compared with $5.88 million in 2019. The previous period was -$57.89 million in 2024. Find out what analysts predict for Celularity in the coming months.

Over the last 6 years, Celularity's total revenue changed from $3.75 million in 2019 to $0.00 in 2025, a change of -100.0%.

In the past 10 quarters, Celularity's cash and equivalents has ranged from $120 thousand in Q3 2025 to $1.90 million in Q1 2024, and is currently $368 thousand as of their latest financial filing in Q1 2026.

Celularity had total debt of $42.54 million at the end of 2025, a 35.1% decrease from 2024, and a 225,171.4% increase since 2019.

Over the last 6 years, Celularity's book value per share changed from 0.14 in 2019 to -1.34 in 2025.


Related Companies

Financial statements for NASDAQ:CELU last updated on 9/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Elon Musk about to bankrupt Amazon, Microsoft & Google?
Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...
Brownstone Research | Sponsoredtc pixel
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...
Weiss Ratings | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
The Claude AI company doubled in value... you missed it
In May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...
Crypto 101 Media | Sponsoredtc pixel
This link won't stay free
The 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...
Profits Run | Sponsoredtc pixel